Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

Phase 2 Completed 16 enrolled University of Chicago National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or recurrent liver, bile duct, or gallbladder cancer.

Timeline

Start: 1999-01
Primary completion: 2000-06
Completion: 2003-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dolastatin 10	Peptide	400 ug/m2	Intravenous

Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

Summary

Timeline

Drugs

Indications